Juno Pharmaceuticals, a biopharmaceutical company, completed the acquisition of Omega Laboratories, a domestic specialty injectable pharmaceutical manufacturer. Financial terms were not disclosed. “We are proud of this acquisition that solidifies Juno’s ability to improve drug supply with medications that are critically needed to support our healthcare system. We are Canadian owned and operated and will continue to support our domestic market while expanding into new geographies with dependable and high-quality Canadian-made pharmaceuticals,” Mark Mantel, Juno CEO.